Outlook Therapeutics secures FDA reversal of its December 2025 CRL, with OND confirming efficacy of LYTENAVA™ in wet AMD. A June 2026 BLA resubmission could trigger a 60‑day Class 1 review.
Written By: Nalam karthik, PharmD
Reviewed By: Pharmacally Editorial Team
Outlook Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted its appeal following a Formal Dispute Resolution (FDR) process tied to the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ in wet age-related macular degeneration (AMD).
The FDA’s Office of New Drugs (OND) concluded that available evidence establishes the efficacy of LYTENAVA™, reversing the agency’s December 2025 Complete Response Letter (CRL), which had questioned the sufficiency of the clinical evidence package.
Clinical Evidence Base
The OND’s decision was grounded in results from the pivotal Phase 3 NORSE TWO study, which evaluated intravitreal LYTENAVA™ in patients with neovascular AMD and served as the primary efficacy trial supporting the BLA. Confirmatory findings from NORSE EIGHT, along with mechanistic, pharmacodynamic, and natural history data, further strengthened the evidence package and established substantial evidence of effectiveness.
The OND also instructed the Division of Ophthalmology and the Office of Specialty Medicine to work with the company on final product labeling.
Regulatory Path Ahead
Outlook Therapeutics plans to resubmit the BLA in June 2026. If accepted as a Class 1 resubmission, the FDA could issue a regulatory decision within 60 days of receipt.
The accelerated review timeline marks a significant shift following the earlier CRL and provides a defined pathway toward potential approval in the United States.
Therapeutic Profile
LYTENAVA™ (bevacizumab-vikg) is an ophthalmic formulation of bevacizumab developed specifically for intravitreal administration in retinal disease.
The monoclonal antibody binds vascular endothelial growth factor (VEGF), blocking VEGF receptor signaling and reducing abnormal retinal blood vessel growth, vascular leakage, and endothelial proliferation associated with wet AMD.
If approved, LYTENAVA™ would become the first FDA-approved ophthalmic bevacizumab supported by validated manufacturing, formal labeling, and post-market pharmacovigilance.
Global Outlook
Outside the United States, LYTENAVA™ already holds centralized marketing authorization in the European Union and approval from the UK Medicines and Healthcare products Regulatory Agency for wet AMD.
Commercial launch in some European markets remains dependent on pricing and reimbursement approvals.
Company Statement
Chief Executive Officer Bob Jahr said the FDA’s decision provides a “clear path forward” toward potential U.S. approval and reaffirmed the company’s commitment to expanding treatment options for patients with neovascular AMD.
Market Significance
Wet AMD remains a leading cause of vision loss among older adults. While anti-VEGF therapies have transformed treatment, physicians in the United States frequently rely on repackaged oncology formulations of bevacizumab because of lower cost, raising concerns around sterility, product consistency, and regulatory oversight.
An FDA-approved ophthalmic formulation of bevacizumab could help address those limitations while expanding access to regulated anti-VEGF therapy in retinal disease.
Reference
About the Writer
Nalam Karthik (LinkedIn) is a healthcare writer and PharmD graduate with interests in pharmacovigilance, drug safety, clinical data analysis, and quality assurance. He is passionate about translating clinical and pharmaceutical knowledge into accessible healthcare content while staying engaged with advancements in drug development and patient safety initiatives.